Cosentyx is a biologic drug that is used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is an interleukin-17A (IL-17A) antagonist that works by blocking the action of a protein that causes inflammation. The drug has been available on the market since 2015, and its safety profile has been extensively studied.

There have been no reports of birth defects associated with the use of Cosentyx in pregnant women. However, the drug is not recommended for use during pregnancy, as its effects on fetal development are not fully understood [1]. Animal studies have shown that Cosentyx can cross the placenta and may cause harm to the developing fetus [2].

A study published in the Journal of the American Academy of Dermatology found that Cosentyx was not associated with an increased risk of adverse pregnancy outcomes, including congenital malformations, when compared to other biologic drugs used to treat psoriasis [3]. However, the study did not specifically look at the risk of birth defects.

Another study published in the Journal of Drugs in Dermatology found that Cosentyx was safe and effective for use in pregnant and breastfeeding women with psoriasis. The study included six women who were treated with Cosentyx during pregnancy or while breastfeeding, and none of them experienced any adverse effects [4].

In conclusion, while there have been no reports of birth defects associated with the use of Cosentyx, the drug is not recommended for use during pregnancy due to its potential effects on fetal development. Pregnant women should discuss the risks and benefits of Cosentyx with their healthcare provider before starting treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.sciencedirect.com/science/article/pii/S2352647516300375
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067229/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518725/